お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:間葉系幹細胞:進歩と応用 (2021年)
市場調査レポート
商品コード
986212

間葉系幹細胞:進歩と応用 (2021年)

Mesenchymal Stem Cells - Advances and Applications, 2021

出版日: | 発行: BIOINFORMANT WORLDWIDE, LLC | ページ情報: 英文 276 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
間葉系幹細胞:進歩と応用 (2021年)
出版日: 2021年04月13日
発行: BIOINFORMANT WORLDWIDE, LLC
ページ情報: 英文 276 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

今日の再生医療で使用されている最も一般的な幹細胞タイプとして、間葉系幹細胞 (MSC) 市場内での成長の大きな可能性があります。 MSCについては10万を超える科学出版物が発表されており、世界中で1,100を超えるMSC臨床試験が進行中です。 MSC臨床試験の現在の「ホットスポット」には、米国、EU、中国、中東、韓国が含まれます。多くの初期段階のMSC試験で安全性と有効性が実証されていますが、商品化されたMSC製品はごくわずかであり、MSCの治療市場は初期段階のままであることを示しています。人口の高齢化と慢性疾患の有病率の増加も、MSCベースの治療への関心を高めています。さらに、Googleトレンドのデータによると、MSC検索は次に一般的な幹細胞タイプの2倍以上一般的です。近年、MSCとMSCベースの調査製品の両方の需要が急増しています。

当レポートでは、世界の間葉系幹細胞(MSC)市場について調査し、主要企業98社の活動について詳細に分析しており、5年間の市場予測とともに、地域・事業セグメント別による市場規模の詳細データを提供しています。

目次

第1章 レポートの概要

  • レポートのステートメント
  • ターゲット人口統計
  • レポートソース
  • レポートの目的
  • エグゼクティブサマリー
  • イントロダクション

第2章 間葉系幹細胞(MSCS):概要

  • 再生医療に対するMSCの影響
  • MSCの命名法のタイムライン
  • MSCのソース
    • 骨髄由来MSC(BM-MSC)
    • 脂肪由来MSC(AD-MSC)
    • 臍帯由来MSC(UC-MSC)
  • MSCの細胞表面マーカー
  • MSCのインビトロ分化能
  • MSC別分泌される可溶性因子

第3章 間葉系幹細胞の製造

  • MSCの分離方法
  • 従来の培養からバイオリアクターへ
    • 単層培養システム
    • バイオリアクターベースの細胞増殖
    • 撹拌槽型バイオリアクター
    • ロッキングバイオリアクター
    • 中空糸バイオリアクター
    • 固定床バイオリアクター
    • 細胞の分離と分離
    • 細胞の洗浄と濃縮
    • 安全性と効力のアッセイ
    • MSC製造中の識別のための表面マーカー

第4章 自家および同種MSC製造の比較

  • 製造原価の比較
    • コスト差
    • ドナーのスクリーニングとテストの費用
    • リリーステストのコスト
  • 2つのビジネスモデルの比較
    • 免疫反応のリスク
    • 相互汚染のリスク
    • 商業的に魅力的なオプション
  • MSC製造におけるコストの内訳
  • コスト削減の機会
  • 部分自動化と完全自動化
    • 部分的な自動化:最も魅力的なオプション

第5章 MSCSの小規模プロセッシング

  • モデル設計
  • 培地

第6章 MSCSの大規模拡張

  • 大規模拡張のための4つの一般的なバイオプロセシング戦略
  • 大規模拡張に一般的に使用されるMSCのソース
  • MSCの大規模拡張に一般的に使用される培地
    • 異なる培地で達成された発泡倍率
  • 大規模なバイオプロセシング戦略の比較
  • 細胞治療の委託製造
    • 契約製造組織(CMO)
    • 契約開発および製造組織(CDMO)
  • 世界の細胞治療製造能力
    • 米国の主要な細胞療法CMO / CDMO
    • 欧州における細胞治療製造のための主要なCMO / CDMO

第7章 業界におけるMSCSの推定消費量

  • 学術および前臨床環境でのMSCの消費
  • 臨床現場でのMSC消費
  • 臨床試験における標的適応症別MSCの消費
  • 将来の消費予測
    • MSC治療薬の消費
    • 人工組織および臓器の消費
    • MSC派生製品別MSC消費
    • 新興産業におけるMSC消費
  • 臨床試験で使用される患者あたりのMSCのコスト:適応症別

第8章 MSCSで公開された科学論文

  • 比較したMSCとiPSCに関する論文数
  • MSCに関する論文数:ソース別
  • MSCを含む臨床試験で発表された論文の数
    • 特定の疾患に対してMSCを使用した臨床試験に関する論文の数

第9章 MSCS、MSCベースのCOVID-19、MSC-エクソソームの臨床試験

  • ClinicalTrials.govからのデータの分析
  • 臨床試験のためのMSCのソース
  • 自家MSCと同種MSC
  • MSCベースの臨床試験の地域分布
    • MSCベースの臨床試験に関与する主要国
  • MSCベースの臨床試験のための資金の種類
  • MSCベースの臨床試験の種類
  • 開発段階別のMSCベースの臨床試験
  • COVID-19の治療のためのMSCを含む臨床試験
    • MSCベースのCOVID-19臨床試験:地域別
  • MSC由来のエクソソームを含む臨床試験
  • MSC調査のためのNIH資金
  • MSCプロジェクトのためのCIRMの資金
    • MSCベースの臨床試験のためのCIRM資金

第10章 現在の最適以下の臨床転帰&解決策

  • MSC製造から生じる課題を克服するため
    • MSC製品の不均一性
  • 凍結保存と文化の救助
    • MSC機能を高めるバイオエンジニアリングソリューション
    • 抗がん剤「Trogan Horses」を運ぶためのMSCのエンジニアリング
  • 注入に関連する臨床的課題の克服
    • 地方行政
    • 不十分な保持と生存
    • 地方行政を改善するための戦略
  • ホストからの臨床的課題を克服するため

第11章 MSCSの変更

  • 遺伝子組み換え
    • 移行を改善するための遺伝子組み換え
    • 接着を改善するための遺伝子組み換え
    • 生存率を改善するための遺伝子組み換え
    • 早期老化を減らすための遺伝子組み換え
  • 前処理の変更
    • 移行を改善するための前処理
    • 接着性を改善するための前処理
    • 生存率を改善するための前処理
    • 老化を減らすための前処理
  • 改変MSCの治療への応用
    • 神経学的状態のための改変MSC
    • 心血管疾患のための改変MSC
    • 肺損傷のための改変MSC
    • 糖尿病のための改変MSC

第12章 臨床試験でMSCSが対処する主要な疾患

  • 自己免疫疾患に対するMSCを使用した臨床試験
  • 心血管疾患に対するMSCを使用した臨床試験
  • 神経変性疾患に対するMSCを使用した臨床試験
  • 骨および軟骨疾患に対するMSCを使用した臨床試験

第13章 間葉系幹細胞産業の現状

  • 研究および臨床応用のためのMSCのソース
  • 牽引力を獲得している同種異系製品
  • マーケティング承認のあるMSCベースの製品
    • Alofisel
    • Stemirac
    • Stempeucel
    • Temcell HS
    • Neuronata-R
    • Prochymal (Remestemcel-L)
    • Cupistem
    • Cartistem
    • Cellgram-AMI
    • Queencell
  • 現在販売されているMSCベースの骨マトリックス
    • Osteocel
    • AlloStem
    • Cellentra VCBM
    • HiQCell
    • Trinity ELITE
    • Map3
    • Trinity Evolution
    • Carticel
    • Chondron
    • DeNovo NT
    • Chondrocelect
    • Ossron
    • JACC
    • MACI
    • Ortho-ACI
    • Spherox
    • Ossgrow
    • Cartigrow
    • ViviGen
    • Bio4
    • Cartiform
  • 全細胞MSC療法からMSC由来のエクソソーム療法へ
    • MSC由来のエクソソームの利点
    • MSC由来のエクソソームの内容
    • 診断としてのエクソソーム
    • ドラッグデリバリーベクターとしてのエクソソーム
  • COVID-19のMSCベースの治療
  • MSCベースのクリーンミート生産
  • 幹細胞ベースの化粧品
    • 市販の幹細胞ベースの化粧品

第14章 市場分析

  • MSCベースの細胞療法(CT)治療の値札
  • MSCベースのマトリックスの値札
  • MSCベースの治療法の市場規模
  • MSCベースの治療薬の世界市場
  • 間葉系幹細胞(MSC)の世界における需要
    • 学術および前臨床調査に必要なMSC
    • 臨床試験に必要なMSC
    • MSCベースの治療法の開発に必要なMSC
    • MSC派生製品の開発に必要なMSC
    • 新興産業に必要なMSC
    • 間葉系幹細胞の世界の市場規模
  • MSCベースの事業セグメントの市場シェア

第15章 企業プロファイル

  • 101 Bio
  • Adipomics, Inc.
  • Aegle Therapeutics
  • Aethlon Medical, Inc.
  • AgeX Therapeutics, Inc.
  • Alexerion Biotech Corp.
  • AlloSource, Inc.
  • American CryoStem Corporation
  • American Type Culture Collection (ATCC)
  • AMS Bio, Ltd. (AMSBIO)
  • Anemocyte S.r.l
  • Anjarium Biosciences
  • Anterogen, Co., Ltd.
  • Apceth Biopharma GmbH
  • Assay Development
  • Aruna Bio
  • Athersys, Inc.
  • Avalon GloboCare Corp.
  • Axol Bioscience, Ltd.
  • Azymus Therapeutics
  • BioCat GmbH
  • BioFluidica
  • Bio-Techne
  • BioVision, Inc.
  • Baylx, Inc.
  • BrainStorm Cell Therapeutics
  • Capricor Therapeutics
  • Catalent Pharma Solutions
  • CCRM
  • CellResearch Corporation, Pte Ltd.
  • Celltex Therapeutics Corporation
  • Ciloa
  • Codiak Biosciences
  • Corestem, Inc.
  • CO-DON AG
  • Cognate Bio, Inc.
  • Creative Bioarray
  • Creative Biolabs
  • Cynata Therapeutics, Ltd.
  • DePuy Synthes
  • Direct Biologics
  • EVerZom
  • Evox Therapeutics, Ltd.
  • Exerkine Corp.
  • Clinical Development
  • ExoCan Healthcare Technologies, Pvt. Ltd.
  • ExoCoBio, Co., Ltd.
  • Exogenus Therapeutics
  • EXoPERT
  • Exopharm
  • Exosome Diagnostics, Inc.
  • ExoDx Prostate Test
  • ExosomePlus
  • Exosome Sciences
  • Exosomics S.p.A
  • Fraunhofer Institute for Cell Therapy and Immunology
  • HansaBioMed Life Sciences, Ltd.
  • Hope Biosciences, LLC
  • Hope's Cell Culture Process
  • Japan Tissue Engineering, Co., Ltd.
  • JCR Pharmaceuticals, Co., Ltd.
  • Kimera Labs, Inc.
  • Lonza Group Ltd.
  • Mantra Bio
  • Medipost, Co., Ltd.
  • MDimune
  • NanoSomix, Inc.
  • NanoView Biosciences
  • NeurExo Sciences
  • Nipro Corporation
  • Stemirac
  • Novus Biologicals, LLC
  • Exosomes Research Tools
  • NuVasive, Inc.
  • Osteocel Family
  • OmniSpirant Limited
  • Orthocell, Ltd.
  • Orthofix Medical, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell, Co., Ltd.
  • Pluristem Therapeutics, Inc.
  • Regeneus, Ltd.
  • HiQCell
  • Regrow Biosciences, Pvt., Ltd.
  • ReNeuron
  • RoosterBio
  • RoslinCT
  • RTI Surgical, Inc.
  • Sentien Biotechnologies, Inc.
  • STEMCELL Technologies, Inc.
  • Stemedica Cell Technologies, Inc.
  • Stemmatters Biotechnologia e Medicina Regenerative SA
  • Stempeutics Research, Pvt., Ltd.
  • System Biosciences, LLC
  • Takeda Pharmaceuticals U.S.A., Inc.
  • Alofisel
  • Tempo Bioscience
  • Tavec Pharma
  • United Therapeutics Corp.
  • Vericel Corporation
  • Versatope Therapeutics
  • Vesigen Therapeutics, Inc.
  • Waisman Biomanufacturing
  • WuXi Advanced Therapies
  • XOStem, Inc.
  • Zen-Bio, Inc.
  • Zimmer Biomet
目次

EXECUTIVE SUMMARY

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth.

Naturally, a broad range of research products have been developed around MSCs and their differentiated cell types. Growing attention is also being given to manufacturing technologies to support commercial-scale production of MSCs. MSCs are well-suited for use in the exponential growth field of 3D printing, because of their capacity to form structural tissues. Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (Evs) and exosomes, because these extracellular "packages" represent a novel strategy for accessing the therapeutic effects of stem cells without the risks of administering whole cells to patients. Finally, gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application.

As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well over 1,100 MSC clinical trials underway worldwide. Current "hotspots" for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. Population aging and an increasing prevalence of chronic disease are also driving interest in MSC-based therapies. Furthermore, Google Trend data reveals that MSC searches are more than twice as common as the next most common stem cell type. The demand for both MSCs and MSC-based research products have surged in recent years.

Today in 2021, nearly one-hundred different market competitors are developing various types of MSC-related products/services, therapies, and manufacturing technologies. Within this ever-changing landscape, having a thorough understanding of the competition and their relative strengths and weaknesses is essential. Therefore, this global strategic report details the activities of 98 leading MSC companies. It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.

With the competitive nature of this global market, you do not have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

The main objectives of this report are to provide the reader with the following details:

  • Market size determination for the global MSC market, segmented by geography and business segment
  • Five-year forecasts for the global MSC market
  • Details of the product candidates being developed by MSC companies
  • MSC market trends, opportunities, risks, and competitive dynamics
  • Major diseases addressed by MSCs in the ongoing clinical trials
  • Cost of manufacturing autologous and allogeneic MSCs
  • Consumption of MSCs for academic research, clinical trials, product development, and exosome production
  • Trend rate data for MSC scientific publications
  • Rates, quantities, geographic locations, and types of MSC clinical trials
  • Types and sources of MSC industry funding
  • Recent business developments related to MSCs
  • MSC-based products with marketing approval and the companies commercializing them
  • Currently marketed MSC-based bone matrices
  • Pricing comparison of MSC-based products with marketing approval
  • Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production and cosmeceuticals
  • Company profiles for 98 MSC market competitors, including their proprietary technologies and products/services under development
  • And so much more

For more comprehensive details about the contents of this report, view the Table of Contents, List of Figures, and List of Tables.

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Founded in 2006 and headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, BioInformant's has unparalleled access to key opinion leaders (KOLs) from across the stem cell sector.

To analyze the rapidly evolving stem cell sector, BioInformant conducts ongoing interviews with prominent executives from across the field. To assess MSC market dynamics, BioInformant interviewed representatives from Cynata Therapeutics (first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and numerous others. As the first and only market research firm to specialize in the stem cell industry, BioInformant is your trusted leader in stem cell industry data.

EXECUTIVE SUMMARY

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth.

Naturally, a broad range of research products have been developed around MSCs and their differentiated cell types. Growing attention is also being given to manufacturing technologies to support commercial-scale production of MSCs. MSCs are well-suited for use in the exponential growth field of 3D printing, because of their capacity to form structural tissues. Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes, because these extracellular "packages" represent a novel strategy for accessing the therapeutic effects of stem cells without the risks of administering whole cells to patients. Finally, gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application.

As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well over 1,100 MSC clinical trials underway worldwide. Current "hotspots" for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. Population aging and an increasing prevalence of chronic disease are also driving interest in MSC-based therapies. Furthermore, Google Trend data reveals that MSC searches are more than twice as common as the next most common stem cell type. The demand for both MSCs and MSC-based research products have surged in recent years.

Today in 2021, nearly one-hundred different market competitors are developing various types of MSC-related products/services, therapies, and manufacturing technologies. Within this ever-changing landscape, having a thorough understanding of the competition and their relative strengths and weaknesses is essential. Therefore, this global strategic report details the activities of 98 leading MSC companies. It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.

With the competitive nature of this global market, you do not have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

The main objectives of this report are to provide the reader with the following details:

  • Market size determination for the global MSC market, segmented by geography and business segment
  • Five-year forecasts for the global MSC market
  • Details of the product candidates being developed by MSC companies
  • MSC market trends, opportunities, risks, and competitive dynamics
  • Major diseases addressed by MSCs in the ongoing clinical trials
  • Cost of manufacturing autologous and allogeneic MSCs
  • Consumption of MSCs for academic research, clinical trials, product development, and exosome production
  • Trend rate data for MSC scientific publications
  • Rates, quantities, geographic locations, and types of MSC clinical trials
  • Types and sources of MSC industry funding
  • Recent business developments related to MSCs
  • MSC-based products with marketing approval and the companies commercializing them
  • Currently marketed MSC-based bone matrices
  • Pricing comparison of MSC-based products with marketing approval
  • Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production and cosmeceuticals
  • Company profiles for 98 MSC market competitors, including their proprietary technologies and products/services under development
  • And so much more

For more comprehensive details about the contents of this report, view the Table of Contents, List of Figures, and List of Tables.

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Founded in 2006 and headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, BioInformant's has unparalleled access to key opinion leaders (KOLs) from across the stem cell sector.

To analyze the rapidly evolving stem cell sector, BioInformant conducts ongoing interviews with prominent executives from across the field. To assess MSC market dynamics, BioInformant interviewed representatives from Cynata Therapeutics (first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and numerous others. As the first and only market research firm to specialize in the stem cell industry, BioInformant is your trusted leader in stem cell industry data.

To analyze the rapidly evolving stem cell sector, BioInformant conducts ongoing interviews with prominent executives from across the field. To assess MSC market dynamics, BioInformant interviewed representatives from Cynata Therapeutics (first company to bring an iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Celularity, Inc. (developing MSC therapeutics from the post-partum human placenta), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and numerous others. As the first and only market research firm to specialize in the stem cell industry, BioInformant is your trusted leader in stem cell industry data.

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.